X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to focus on the advancement of the clinical development of TG4050, an individualized immunotherapy being developed for solid tumors. It is being evaluated in Phase I for the treatment of Squamous Cell Carcinoma of Head and Neck.
Lead Product(s): TG4050
Therapeutic Area: Oncology Product Name: TG4050
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Transgene
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration March 05, 2024
Details:
Under the collaboration, BostonGene will support the Phase I/II study of LCB84, a TROP2-directed antibody-drug conjugate (ADC), in patients with advanced cancers.
Lead Product(s): LCB84,Anti-PD-1 Ab
Therapeutic Area: Oncology Product Name: LCB84
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Recipient: LegoChem Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 07, 2023
Details:
Study finds that tumor behavior specificities linked with patient responses, and the MxIF analyses identified 14 unique cellular neighborhoods in multi-region tumors that can be utilized to optimize treatment strategies for patients with ccRCC.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Washington University School of Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2022
Details:
Transgene’s myvac® platform brings together a series of highly innovative technologies, such as viral genome engineering, to achieve high-speed modular manufacturing of bespoke immunotherapies.
Lead Product(s): TG4050
Therapeutic Area: Oncology Product Name: TG4050
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Transgene
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 06, 2020
Details:
The collaboration aims to define predictors of response to PI3 kinase inhibition in relapsed/refractory T-cell lymphomas.
Lead Product(s): Duvelisib
Therapeutic Area: Oncology Product Name: Copiktra
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: The Weinstock Laboratory
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 04, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
